In response to the recently published summary of the Cochrane Review on 'Systemic treatments for metastatic cutaneous melanoma', I feel it is important to highlight the promising new treatments, in particular, ipilumumab and vermurafenib. Before these drug were introduced, there was no effective ...
Pembrolizumab, an antibody againstprogrammed cell deathprotein 1 (PD-1), is an approvedtreatmentfor unresectable ormetastatic melanoma. The PD-1 pathway limits immune responses to melanoma and can be blocked with pembrolizumab. In this phase 1 clinical trial, 655 patients with advanced or metastatic...
The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma. It is the first drug approved for metastatic, or advanced, melanoma is more than a decade. "Ipilimumab is the first in a new class of drugs that has been ...
TreatmentTargeted therapyImmunotherapyCombination therapyMetastatic melanoma is an aggressive form of cancer characterised by poor prognosis and a complex etiology. Until 2010, the treatment options for metastatic melanoma were very limited. Largely ineffective dacarbazine, temozolamide or fotemustine were ...
S. Treatment of metastatic melanoma with an orally available inhibitor of the Ras–Raf–MAPK cascade. Cancer Res. 63, 5669–5673 (2003). CAS PubMed Google Scholar Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006). ADS CAS PubMed ...
REVIEW British Journal of Cancer (2016) 115, 505–516 | doi: 10.1038/bjc.2016.230 Keywords: systemic therapy; metastatic renal cell carcinoma; T-cell checkpoint inhibitors; tyrosine kinase inhibitors Medical treatment of renal cancer: new horizons Basma Greef*,1 and Tim Eisen2 1Department of ...
临床皮肤科杂志 2013 年 42 卷第 10 期J ClinDermatol熏 October 2013熏 Vol.42熏 No.10 恶性黑素瘤( malignant melanoma,MM) 是一种恶性程度极高、发生隐匿的肿瘤, 年增长率为 3%~5%[1]。 无数的对照研究使用化疗药物、 疫苗、 他莫昔芬、 细胞因子如干扰素和白介素( IL) -2, 作为单一疗法或联合...
New European approval: Relatlimab/nivolumab in first -line treatment of advanced metastatic melanoma with less than 1% tumor expression of PD-L1 来自 NCBI 喜欢 0 阅读量: 9 作者:M Boileau,L Boussemart 关键词: Immune checkpoint inhibitor Melanoma Mélanome Nivolumab Points de contrôle imm...
Neoadjuvant treatment in locally advanced melanoma: premises The development of new immunotherapies (monoclonal antibodies specific for cytotoxic T lymphocyte-associated Figure 1 CT scan, October 2012 (before vemurafenib therapy). Abbreviation: CT, computed tomography. 1116 submit your manuscript | www....
The ongoing CoBRIM study enrolled 495 treatment-naivepatientswith BRAFV600-mutation-positive unresectable locally advanced ormetastatic melanoma. Patients were randomised to received a 28-day treatment cycle of vemurafenib (960 mg, twice daily), and either cobimetinib or placebo (60 mg daily from days...